Combination therapy and new types of agents for pulmonary arterial hypertension

被引：35

作者：

O'Callaghan, Dermot ^{[1
]}

Gaine, Sean P. ^{[1
]}

机构：

[1] Mater Misericordiae Univ Hosp, Univ Coll Dublin, Dept Resp Med, Dublin 7, Ireland

来源：

CLINICS IN CHEST MEDICINE | 2007年 / 28卷 / 01期

关键词：

D O I：

10.1016/j.ccm.2006.11.011

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

This review assesses the available evidence supporting the use of drug combinations for the management of the various forms of pulmonary arterial hypertension (PAH). Ongoing and forthcoming randomized trials evaluating this strategy are also highlighted. Furthermore, new types of agents to treat PAH in the future are explored.

引用

页码：169 / +

页数：18

共 108 条

[1]

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats [J].

Abe, K ;

Shimokawa, H ;

Morikawa, K ;

Uwatoku, T ;

Oi, K ;

Matsumoto, Y ;

Hattori, T ;

Nakashima, Y ;

Kaibuchi, K ;

Sueishi, K ;

Takeshita, A .

CIRCULATION RESEARCH, 2004, 94 (03) :385-393

[2]

Lessons learned from cancer may help in the treatment of pulmonary hypertension [J].

Adnot, S .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1461-1463

[3]

Sildenafil ameliorates effects of inhaled nitric oxide withdrawal [J].

Atz, AM ;

Wessel, DL .

ANESTHESIOLOGY, 1999, 91 (01) :307-310

[4]

Sitaxsentan improves time to clinical worsening in patients with pulmonary arterial hypertension [J].

Badesch, D ;

Galie, N ;

Langleben, D ;

Naeije, R ;

Simonneau, G ;

Barst, R .

CHEST, 2005, 128 (04) :160S-161S

[5]

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[6]

Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].

Badesch, DB ;

Abman, SH ;

Ahearn, GS ;

Barst, RJ ;

McCrory, DC ;

Simonneau, G ;

McLaughlin, VV .

CHEST, 2004, 126 (01) :35S-62S

[7]

Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[8]

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[9]

Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[10]

SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].

BARST, RJ ;

RUBIN, LJ ;

MCGOON, MD ;

CALDWELL, EJ ;

LONG, WA ;

LEVY, PS .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415

← 1 2 3 4 5 6 7 8 9 10 →